Stocks That Hit 52-Week Lows On Monday
Benzinga Insights 5 years ago
NewsIntraday UpdateMarketsMoversTrading Ideas
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows.
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows.
Interesting Highlights:
- The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (NASDAQ:IONS).
- The smallest company by market cap to hit a new 52-week low was Millendo Therapeutics (NASDAQ:MLND).
- Qualigen Therapeutics (NASDAQ:QLGN)'s stock dropped the most, trading down 14.23% to reach a new 52-week low.
During the first half-hour of trading on Monday, the following stocks set new 52-week lows:
- Ionis Pharmaceuticals (NASDAQ:IONS) stock set a new 52-week low of $41.19 on Monday, moving down 2.14%.
- Sarepta Therapeutics (NASDAQ:SRPT) stock set a new 52-week low of $68.51 on Monday, moving down 1.74%.
- Nikola (NASDAQ:NKLA) stock dropped to a yearly low on Monday of $12.02. Shares traded down 3.36%.
- ACADIA Pharmaceuticals (NASDAQ:ACAD) shares reached a new 52-week low of $20.13 on Monday morning, moving up 0.12%.
- Reata Pharmaceuticals (NASDAQ:RETA) shares moved down 2.02% on Monday to hit a new 52-week low of $86.00, drifting down 2.02%.
- Telecom Argentina (NYSE:TEO) stock hit $5.20 on Monday morning, setting a new 52-week low for a change of up 0.38%.
- Axsome Therapeutics (NASDAQ:AXSM) stock achieved a new 52-week low on Monday morning, hitting $51.55 and moving down 2.02%.
- Coherus BioSciences (NASDAQ:CHRS) shares fell to $13.69 on Monday, setting a new 52-week low with a shift of down 1.58%.
- Adverum Biotechnologies (NASDAQ:ADVM) stock set a new 52-week low of $8.90 on Monday, moving down 1.43%.
- Vasta Platform (NASDAQ:VSTA) shares made a new 52-week low of $8.73 on Monday. The stock was down 4.03% for the day.
- BEST (NYSE:BEST) stock hit a new 52-week low of $1.55. The stock was down 0.75% on the session.
- Sigilon Therapeutics (NASDAQ:SGTX) shares hit a yearly low of $16.74. The stock was up 0.23% on the session.
- Atreca (NASDAQ:BCEL) shares moved down 2.6% on Monday to hit a new 52-week low of $11.88, drifting down 2.6%.
- Syros Pharmaceuticals (NASDAQ:SYRS) stock achieved a new 52-week low on Monday morning, hitting $6.32 and moving down 2.14%.
- Puxin (NYSE:NEW) shares reached a new 52-week low of $3.38 on Monday morning, moving down 3.72%.
- Puyi (NASDAQ:PUYI) shares moved down 1.93% on Monday to hit a new 52-week low of $4.05, drifting down 1.93%.
- Lannett (NYSE:LCI) stock hit a new 52-week low of $4.77. The stock was down 2.52% on the session.
- Assembly Biosciences (NASDAQ:ASMB) shares were down 2.06% for the day, having made a 52-week low of $4.20.
- Calithera Biosciences (NASDAQ:CALA) stock drifted down 3.06% on Monday morning to hit a new 52-week low of $2.23.
- ContraFect (NASDAQ:CFRX) stock drifted down 1.43% on Monday morning to hit a new 52-week low of $4.04.
- NeuBase Therapeutics (NASDAQ:NBSE) shares hit a yearly low of $6.17. The stock was down 0.92% on the session.
- Concert Pharmaceuticals (NASDAQ:CNCE) stock achieved a new 52-week low on Monday morning, hitting $4.45 and moving down 1.75%.
- CooTek (Cayman) (NYSE:CTK) shares moved down 7.48% on Monday to hit a new 52-week low of $2.31, drifting down 7.48%.
- TD Hldgs (NASDAQ:GLG) shares were down 11.88% for the day, having made a 52-week low of $1.34.
- Metacrine (NASDAQ:MTCR) shares fell to $5.10 on Monday, setting a new 52-week low with a shift of down 0.39%.
- Imara (NASDAQ:IMRA) stock hit a new 52-week low of $7.43. The stock was down 1.5% on the session.
- Qualigen Therapeutics (NASDAQ:QLGN) stock drifted down 14.23% on Monday morning to hit a new 52-week low of $2.15.
- Idera Pharmaceuticals (NASDAQ:IDRA) stock dropped to a yearly low on Monday of $1.21. Shares traded down 3.57%.
- Astrotech (NASDAQ:ASTC) shares moved down 6.12% on Monday to hit a new 52-week low of $1.35, drifting down 6.12%.
- Millendo Therapeutics (NASDAQ:MLND) stock dropped to a yearly low on Monday of $1.12. Shares traded down 0.86%.
Benzinga will update traders on these companies going forward. If these companies break to a new level, Benzinga will be the first to report on it.